Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Shitara, Kohei; Doi, Toshihiko; Dvorkin, Mikhail; Mansoor, Wasat; Arkenau, Hendrik-Tobias; Prokharau, Aliaksandr; Alsina, Maria; Ghidini, Michele; Faustino, Catia; Gorbunova, Vera; Zhavrid, Edvard; Nishikawa, Kazuhiro; Hosokawa, Ayumu; YALÇIN, ŞUAYİB; Fujitani, Kazumasa; Beretta, Giordano; Van Cutsem, Eric; Winkler, Robert; Makris, Lukas; Ilson, David; Tabernero, Josep

doi:10.1016/s1470-2045(18)30739-3

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Copy For Citation

Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., ...More

LANCET ONCOLOGY, vol.19, no.11, pp.1437-1448, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 19 Issue: 11
Publication Date: 2018
Doi Number: 10.1016/s1470-2045(18)30739-3
Journal Name: LANCET ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1437-1448
Hacettepe University Affiliated: Yes

Abstract

Background Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population.